Indication
Migraine
The Migraine pipeline: 53 tracked drugs, 45 approved for this indication.
45 approved / phase 43 Phase 31 Phase 2/32 Phase 22 preclinical / unstaged
Compare the share prices of listed companies in Migraine →
Total attributable cost
$175.4B
$11,010/patient
Drug spend
Not yet sourced
any · US